Diabetes Disparities: Texting to Extend Treatment (DD-TXT)
N/A
Completed
NCT04227379
| Condition | Diabetes Mellitus, Type 2 |
|---|
| Phase | N/A |
|---|
| Sponsor | VA Office of Research and Development |
|---|
| Status | Completed |
|---|
| Enrollment | 366 participants |
|---|
| Interventions | Intervention 1- DSMS+, Comparison - DSMS |
|---|
| Start date | Jan 30, 2023 |
|---|
| Completion date | Apr 30, 2025 |
|---|
| Results posted | Jun 1, 2026 |
|---|
Summary
One way to help Veterans improve their diabetes control is through the use of technology to help provide information, motivation, and reminders necessary to support diabetes self-management. The study will seek input from diverse groups of Veterans living with diabetes to help develop a new customizable, interactive texting intervention that allows Veterans to choose what kinds of diabetes self-management support they need, and when. This diabetes support will be provided to Veterans through "Annie for Veterans", a VA texting system for self-management support. Patients will be randomized to receive a once-daily standard diabetes self-management texting intervention called DSMS based on standard diabetes self-management education content or a customizable, patient-centered diabetes self-management support intervention with additional features called DSMS Plus (DSMS+) in order to test the comparative effectiveness of these two texting interventions.
Change in HbA1c Percent Time in Control
pre-enrollment, 6 month follow up · percent (%) of time in control
| DSMS | 23.41 ± 34.96 percent (%) of time in control |
|---|
| DSMS+ (DSMS Plus) | 21.61 ± 40.55 percent (%) of time in control |
|---|
| p-value | .6519 |
| Mean Difference (Net) | 1.80 (95% CI -6.05–9.65) |
Change in HbA1c
pre-enrollment, 6 month follow-up · Percentage of glycosylated hemoglobin
| DSMS | -0.36 ± 1.37 Percentage of glycosylated hemoglobin |
|---|
| DSMS+ (DSMS Plus) | -0.40 ± 1.29 Percentage of glycosylated hemoglobin |
|---|
| p-value | .7552 |
| Mean Difference (Net) | .05 (95% CI -.25–.34) |
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.